Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.

doi:10.1111/bjh.16988

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.

British journal of haematology - 1 Mar 2021

Alvarez-Larrán Alberto, Angona Anna, Andrade-Campos Marcio, Soledad Noya M, Teresa Gómez-Casares M, Cuevas Beatriz, Caballero Gonzalo, García-Hernández Carmen, García-Gutiérrez Valentín, Palomino Alicia, Ferrer-Marín Francisca, Isabel Mata-Vázquez M, Moretó Ana, Magro Elena, Murillo Ilda, Manuel Alonso-Domínguez Juan, María Guerra José, Guerrero Lucía, María Raya José, Pérez-Encinas Manuel, Carreño-Tarragona Gonzalo, Fox Laura, Pastor-Galán Irene, Bellosillo Beatriz, Hernández-Boluda Juan Carlos

Abstract excerpt

The present study assessed the criteria for initiating cytoreduction and response to conventional therapies in 1446 patients with essential thrombocythemia (ET), 267 (17%) of which were CALR-mutated. In low risk patients, time from diagnosis to cytoreduction was shorter in CALR-positive than in the other genotypes (2·8, 3·2, 7·4 and 12·5 years for CALR, MPL, JAK2V617F and TN, respectively, P < 0·0001). A total of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Hydroxyurea

Share to Janus Kinase 2

Share to Quinazolines

Share to Registries

Share to Spain

Share to Thrombocythemia, Essential

Source

Open in PubMed

Identifiers

PMID: 32745264
DOI: 10.1111/bjh.16988

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.PMID 32745264Read ↗

Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.Semantic proximity Read ↗

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.Semantic proximity Read ↗

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.Semantic proximity Read ↗

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.Semantic proximity Read ↗

The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.Semantic proximity Read ↗

Analysis of CALR-mutated essential thrombocythemia as a distinct disease entity compared with JAK2 V617F-mutated and triple-negative patients.Semantic proximity Read ↗

Anagrelide and Mutational Status in Essential Thrombocythemia.Semantic proximity Read ↗

A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.Semantic proximity Read ↗

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.Semantic proximity Read ↗

A rare CALR variant mutation and a review of CALR in essential thrombocythemia.Semantic proximity Read ↗

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.Semantic proximity Read ↗

[Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.